She probably gets paid to trash stocks. That's how the game is played in biotech surrounding news releases. She's like Fuerstein, just cheaper. She projected when she tweeted, "Pure filth."
The lack of comprehension of $avxl holders is only a problem on a short enough time scale. If you are willing to hold this garbage into any kind of FDA interaction, where naturally regulators are not down with 2/11 endpoint “success rate”, and 9/11 fail rate, it’s a win-win